Wegovy is one component of Tias Metabolic Health & Weight Loss Program - a womens-specific program designed to identify the root causes of weight and metabolic changes, screen for insulin resistance and related conditions, and build a personalized, evidence-based plan that may include GLP-1 medications like Wegovy when clinically appropriate
This prespecified analysis of STEP-HFpEF investigated the efficacy of semaglutide versus placebo in patients with HFpEF across the different classes of obesity, as it pertains to the primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite endpoint (comprising all-cause death, HF events, several thresholds of change in KCCQ-CSS and change in 6MWD 30 m) and change in C-reactive protein (CRP)), and it tested whether the degree of body weight reduction achieved on treatment with semaglutide was related to the improvements in the key trial endpoints
A prospective cohort study of more than 50,000 women did not observe a difference between rates of cataract extraction between women in the highest quintile of riboflavin intake (median of 1.5 mg/day) and women in the lowest quintile (median of 1.2 mg/day) (36)
Delayed Gastric Emptying Because GLP-1s slow down the rate at which your stomach empties, they can change the timing of when your levothyroxine reaches your small intestine for absorption
